See every side of every news story

Published 11 days ago • loading... • Updated 10 days ago

FDA Grants Fast Track Designation to Promising Multiple System Atrophy Agent Amlenetug

Summary by neurologylive.com

Amlenetug, a human monoclonal antibody that recognizes and binds to all major forms of extracellular α-synuclein, is currently being assessed in a large-scale phase 3 trial to determine its therapeutic potential as a treatment for MSA.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

2 Articles

All

Left

Center

Right

neurologylive.com

FDA Grants Fast Track Designation to Promising Multiple System Atrophy Agent Amlenetug

Amlenetug, a human monoclonal antibody that recognizes and binds to all major forms of extracellular α-synuclein, is currently being assessed in a large-scale phase 3 trial to determine its therapeutic potential as a treatment for MSA.

Read Full Article

pharmatimes.com

Amlenetug receives FDA Fast Track Designation

Potential treatment for multiple system atrophy shows promise

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources2

Leaning Left0Leaning Right0Center0Last Updated9 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmatimes.com broke the news in 11 days ago on Wednesday, February 12, 2025.

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics